|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
CA3210167A1
(en)
*
|
2021-02-09 |
2022-08-18 |
Genentech, Inc. |
Tetracyclic oxazepine compounds and uses thereof
|
|
CA3211725A1
(en)
*
|
2021-03-17 |
2022-09-22 |
Tao Jiang |
Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
|
|
EP4361157A4
(en)
*
|
2021-06-21 |
2024-10-16 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
|
|
TW202315626A
(zh)
*
|
2021-08-31 |
2023-04-16 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
EP4471037A1
(en)
*
|
2022-01-30 |
2024-12-04 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Quinoline compound and use thereof
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CR20240451A
(es)
*
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
CA3247639A1
(en)
|
2022-05-06 |
2023-11-09 |
PAQ Therapeutics Inc. |
CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
|
|
CR20240508A
(es)
*
|
2022-05-19 |
2024-12-20 |
Genentech Inc |
Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024022444A1
(zh)
*
|
2022-07-27 |
2024-02-01 |
江苏恒瑞医药股份有限公司 |
稠环类化合物、其制备方法及其在医药上的应用
|
|
AU2023314335A1
(en)
*
|
2022-07-29 |
2025-02-27 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising kras g12d inhibitor
|
|
IL318647A
(en)
|
2022-08-05 |
2025-03-01 |
Kumquat Biosciences Inc |
Heterocyclic compounds and their uses
|
|
WO2024032704A1
(en)
*
|
2022-08-11 |
2024-02-15 |
Beigene, Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
WO2024051721A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
TW202426459A
(zh)
*
|
2022-09-23 |
2024-07-01 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
AU2023388747A1
(en)
*
|
2022-12-07 |
2025-07-10 |
Jacobio Pharmaceuticals Co., Ltd. |
Fused cyclic compounds and use thereof
|
|
EP4640689A1
(en)
*
|
2022-12-20 |
2025-10-29 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Crystal form of kras g12d inhibitor and preparation method therefor
|
|
WO2024153116A1
(en)
*
|
2023-01-18 |
2024-07-25 |
Suzhou Zanrong Pharma Limited |
Kras g12d inhibitors and uses thereof
|
|
WO2024234360A1
(en)
*
|
2023-05-18 |
2024-11-21 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024160225A1
(en)
*
|
2023-02-02 |
2024-08-08 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024159471A1
(en)
*
|
2023-02-02 |
2024-08-08 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024159470A1
(en)
*
|
2023-02-02 |
2024-08-08 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
KR20260041941A
(ko)
|
2023-03-15 |
2026-03-27 |
콴타 테라퓨틱스, 인크. |
Kras 조절 인자 및 이의 용도
|
|
WO2024197503A1
(en)
*
|
2023-03-27 |
2024-10-03 |
Nikang Therapeutics , Inc. |
Tricyclic derivatives as kras inhibitors
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024208305A1
(zh)
*
|
2023-04-07 |
2024-10-10 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
EP4695262A1
(en)
*
|
2023-04-10 |
2026-02-18 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
AU2024252725A1
(en)
*
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
WO2024218686A1
(en)
*
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
CN121100120A
(zh)
*
|
2023-05-07 |
2025-12-09 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2024243186A2
(en)
*
|
2023-05-22 |
2024-11-28 |
Board Of Regents, The University Of Texas System |
Heterocyclic compounds as nras inhibitors
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
IL326812A
(en)
*
|
2023-08-25 |
2026-04-01 |
Ensem Therapeutics Inc |
Tetracyclic substances, preparations containing them and their uses
|
|
WO2025045141A1
(en)
*
|
2023-08-31 |
2025-03-06 |
Suzhou Zanrong Pharma Limited |
Kras inhibitors and uses thereof
|
|
US20250101042A1
(en)
*
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059040A1
(en)
*
|
2023-09-11 |
2025-03-20 |
Newave Pharmaceutical Inc. |
Mutant kras modulators and uses thereof
|
|
CN121941690A
(zh)
|
2023-10-03 |
2026-04-28 |
Paq医疗公司 |
Kras蛋白水解靶向嵌合体
|
|
US20250114339A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
AR134485A1
(es)
*
|
2023-11-22 |
2026-01-21 |
Genentech Inc |
Inhibidores de oxazepina aza-tetracíclica de kras-g12d
|
|
WO2025111586A1
(en)
*
|
2023-11-22 |
2025-05-30 |
Genentech, Inc. |
Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
|
|
WO2025123318A1
(en)
*
|
2023-12-15 |
2025-06-19 |
Shanghai Blueray Biopharma Co., Ltd. |
TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS
|
|
WO2025146194A1
(en)
*
|
2024-01-05 |
2025-07-10 |
Jacobio Pharmaceuticals Co., Ltd. |
Fused tetracyclic compounds and use thereof
|
|
WO2025153038A1
(en)
*
|
2024-01-17 |
2025-07-24 |
Suzhou Zanrong Pharma Limited |
Kras inhibitors and uses thereof
|
|
CN119684315A
(zh)
*
|
2024-01-26 |
2025-03-25 |
苏州盛迪亚生物医药有限公司 |
一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025194134A1
(en)
*
|
2024-03-15 |
2025-09-18 |
Genentech, Inc. |
Linearly substituted oxazepin-5-one kras-g12d inhibitors
|
|
WO2025217319A1
(en)
*
|
2024-04-09 |
2025-10-16 |
Kestrel Therapeutics Inc. |
Ras inhibitors and methods of use thereof
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|